ZSCAN4 and non-small cell lung carcinoma: More importantly, Kaplan–Meier analysis of NSCLC patients indicated that enhanced stromal Zscan4 expression significantly correlates with poor clinical outcome in the treated cohort, with lower Zscan4 expression favoring longer survival (Fig. 2e).